PGIM Jennison Health Sciences FundPHLAX
Type
Mutual fund
Peer group
Global equity
Net assets
$1.5B
Expense ratio
1.15%
1-year return
+16.5%
3 years, a year
+14.3%
5 years, a year
+7.0%
Holdings
51
What it aims to do.
The investment objective of the Fund is long-term capital appreciation .
Top 10 holdings.
| Holding | % of fund |
|---|---|
| LLY Eli Lilly & Co. | 16.77% |
| JOBY (PIPA070) PGIM Core Government Money Market Fund | 7.72% |
| MRK Merck & Co., Inc | 6.02% |
| GILD Gilead Sciences Inc. | 4.37% |
| UNH UnitedHealth Group Inc. | 4.30% |
| VRTX Vertex Pharmaceuticals Incorporated | 3.56% |
| CVS CVS Health Corp | 3.27% |
| JOBY Lonza Group AG | 3.13% |
| ARGX Argenx SE | 3.10% |
| REGN Regeneron Pharmaceuticals, Inc. | 3.07% |
More on PHLAX.
- PHLAX overview
- PHLAX holdings
- PHLAX risk
- PHLAX costs
- PHLAX money in and out
- PHLAX share classes
- Compare PHLAX with other funds
Returns after fees, from the fund's SEC filings up to Feb 2026. Past returns are not a promise. Not financial advice.